Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2007

01-05-2007 | Case Reports

False-positive β-human chorionic gonadotropin values in the follow-up of gestational trophoblastic disease

Authors: V. M. Díaz Muñoz de la Espada, J. A. Arranz Arija, P. Khosravi Shahi, S. Encinas García, R. Álvarez Álvarez, R. González Beca

Published in: Clinical and Translational Oncology | Issue 5/2007

Login to get access
Metadata
Title
False-positive β-human chorionic gonadotropin values in the follow-up of gestational trophoblastic disease
Authors
V. M. Díaz Muñoz de la Espada
J. A. Arranz Arija
P. Khosravi Shahi
S. Encinas García
R. Álvarez Álvarez
R. González Beca
Publication date
01-05-2007
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 5/2007
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-007-0062-z

Other articles of this Issue 5/2007

Clinical and Translational Oncology 5/2007 Go to the issue

Research Articles

Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study

News and Views

High tension: oncologic pain

Editorial

Centralisation of complex pathologies in honours of excellence. How to do it?

Special Article

Treatment guidelines in ovarian cancer

Research Articles

Long-term outcome of a phase II study of weekly docetaxel with a short course of estramustine and enoxaparine in hormone-resistant prostate cancer patients

Educational Series

Cancer epidemiology: study designs and data analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits